YENOM NOTICIAS

Qué está moviendo el mercado.

Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.

MYCOF
Limpiar

Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.

seekingalpha.comPOSITIVO

Noveris Health Sciences to raise up to $500K via 10% convertible debenture private placement

Noveris Health Sciences (MYCOF [https://seekingalpha.com/symbol/MYCOF]) plans to complete a non-brokered private placement [https://seekingalpha.com/pr/20626341-noveris-health-sciences-announces-proposed-private-placement-of-convertible-de…

MYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Announces Update Regarding the Special Access Program

DENVER, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols t…

0NF0.FAQUIS STOCK EXCHANGE:MYIGMYCO-CN.CNMYCO.CNMYCO.NEO
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements

VANCOUVER, British Columbia, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medi…

0NF0.FAQUIS STOCK EXCHANGE:MYIGMYCO-CN.CNMYCO.CNMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Provides Q4 2023 Business Update

VANCOUVER, British Columbia, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative med…

0NF0.FAQUIS STOCK EXCHANGE:MYIGMYCO-CN.CNMYCO.CNMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK

VANCOUVER, British Columbia, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group, Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative…

0NF0.FAQUIS STOCK EXCHANGE:MYIGMYCO-CN.CNMYCO.CNMYCO.NEO
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK and First Day of Dealings

VANCOUVER, British Columbia, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group, Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative…

0NF0.FAQUIS STOCK EXCHANGE:MYIGMYCO-CN.CNMYCO.CNMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO

VANCOUVER, British Columbia, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NF0) a biotechnology company engineering the next wave of innovative medications and…

0NF0.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date

VANCOUVER, British Columbia, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and…

0NFA-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing

VANCOUVER, British Columbia, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA),a biotechnology company engineering the next wave of innovative medications and…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Innovations Announces Closing of Prospectus Supplement Financing

VANCOUVER, British Columbia, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Innovations Group Files Prospectus Supplement

VANCOUVER, British Columbia, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Announces Conditional Approval of CSE Listing

VANCOUVER, British Columbia, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO:MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), is pleased to announce that it has made an application and received condition…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2023

VANCOUVER, British Columbia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company engineering the next wave of innovative medications and treatment pro…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Innovations Group Provides Corporate Update

VANCOUVER, British Columbia, July 21, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Reports its Special Meeting Results

VANCOUVER, British Columbia, July 05, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreement and Provides Update on Its Board of Directors

VANCOUVER, British Columbia, May 29, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and t…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Reports Financial Results for the First Quarter of Fiscal Year 2023

VANCOUVER, British Columbia, May 16, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company engineering the next wave of innovative medications and tr…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Reports its 2023 Annual General Shareholders' Meeting Results

VANCOUVER, British Columbia, May 10, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues

VANCOUVER, British Columbia, April 24, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications an…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Innovations Group Provides Corporate Update

VANCOUVER, British Columbia, April 03, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications an…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Reports Financial Results for the Year Ended December 2022

DENVER, March 31, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, t…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Announces Debt Settlements

DENVER, March 06, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.

DENVER, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols t…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement

DENVER, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols t…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022

DENVER, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, to…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Innovations Group Signs a Letter of Intent to Sell its Wholly-Owned Subsidiary, Mindleap Health Inc.

DENVER, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Innovations Group Announces Common Share Subscription Agreement

DENVER, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Innovations Group Announces Private Placement; Interim Changes to Management and Board of Directors

DENVER, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2022

DENVER, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, to…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs

DENVER, July 19, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorder…

0NF0-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

DENVER, June 17, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology aiming to transform the treatment of mental health and addiction disorders, today anno…

0NF0-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Provides Company Update; Welcomes New Board Member

DENVER, June 09, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorder…

0NF0-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Announces First Quarter 2022 Financial Results and Highlights

DENVER, May 16, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders…

0NF0-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update

MYCO-001 Smoking Cessation Clinical Trial Moves Forward Following Conditional IRB Approval Company Advances IP Portfolio With New Patent Applications Covering Novel Molecule Families DENVER, March 31, 2022 (GLOBE NEWSWIRE) -- Mydecine Inno…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study

DENVER, March 24, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology company aiming to transform the treatment of mental health and addiction disorde…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →
globenewswire.comPOSITIVO

Mydecine To Attend March Investor Conferences

DENVER, March 03, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorde…

0NF-F.FMYCO-NE.NEOMYCO.NEOMYCOF
Fuente original ↗Analizar →